BCV
MYGN icon

Banque Cantonale Vaudoise’s Myriad Genetics MYGN Stock Holding History

Banque Cantonale Vaudoise’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-1,333
Closed -$24K – 1267
2022
Q2 		$24K Sell
1,333
-679
-34% -$14.1K ﹤0.01% 1107
2022
Q1 		$51K Hold
2,012
– – ﹤0.01% 1044
2021
Q4 		$56K Hold
2,012
– – ﹤0.01% 1053
2021
Q3 		$65K Buy
+2,012
New +$66.8K ﹤0.01% 1014

Other funds holding MYGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return

Banque Cantonale Vaudoise's MYGN Position: Q3 2022 in Review

Banque Cantonale Vaudoise sold out of Myriad Genetics (MYGN) in Q3 2022, closing a stake of 1,333 shares — an estimated $24K sold.

Banque Cantonale Vaudoise first reported a position in MYGN in Q3 2021 and held it in 4 quarters. The position peaked at $65K in Q3 2021. 191 funds tracked by Wall St. Rank hold MYGN as of Q3 2022.

  • Banque Cantonale Vaudoise reported no remaining Myriad Genetics position as of Q3 2022 after selling out during the quarter.
  • Banque Cantonale Vaudoise sold 1,333 Myriad Genetics shares in Q3 2022, an estimated $24K.
  • Banque Cantonale Vaudoise first reported a position in Myriad Genetics in Q3 2021 and held it in 4 quarters.
  • Banque Cantonale Vaudoise's Myriad Genetics position peaked at $65K in Q3 2021.
  • 191 funds tracked by Wall St. Rank held Myriad Genetics as of Q3 2022.

Based on Banque Cantonale Vaudoise's 13F filing for Q3 2022, filed 17 Oct 2022.